参考文献/References:
[1] Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis[J]. N Engl J Med, 1991, 325(21): 1487-1498.
[2] Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis[J]. Lancet, 2003, 362(9388): 971-982.
[3] Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria[J]. Rheum Dis Clin North Am, 2002, 28(4): 723-741.
[4] Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies[J]. Curr Opin Pharmacol, 2010, 10(3): 346-352.
[5] Schmidt J, Dalakas MC. Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies[J]. Expert Opin Med Diagn, 2010, 4(3): 241-250.
[6] 张玉慧,宋为民,李志军.特发性炎性肌病的诊断与治疗[J].中华全科医学,2020,18(7):1073-1074.
[7] Espitia-Thibault A, Masseau A, Néel A, et al. Sj?ren’s syndrome-associated myositis with germinal centre-like structures[J]. Autoimmun Rev, 2017, 16(2): 154-158.
[8] Migkos MP, Sarmas I, Somarakis GA, et al. Sj?ren syndrome associated with inflammatory muscle diseases[J]. Mediterr J Rheumatol, 2018, 29(2): 92-96.
[9] Hom J, Marwaha S, Postolova A, et al. A patient with sjogren’s syndrome and subsequent diagnosis of inclusion body myositis and Light-Chain amyloidosis[J]. J Gen Intern Med, 2019, 34(6): 1058-1062.
[10] Benveniste O, Rider LG, ENMC Myositis Outcomes Study Group. 213th ENMC international workshop: outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, heemskerk, the Netherlands, 18-20 September 2015[J]. Neuromuscul Disord, 2016, 26(8): 523-534.
[11] Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies[J]. Autoimmun Rev, 2012, 11(3): 203-206.
[12] 齐海宇,宋淑菊,段婷,等.原发干燥综合征43例临床特点分析[J].中国医刊,2017,52(5):101-103.
[13] 王建军,吕群,龚玲,等.原发性干燥综合征合并间质性肺病患者临床与影像特点分析[J].中华全科医学,2019,17(8):1275-1278.